Safety and Efficacy Assessment of Two New Leprosy Skin Test Antigens: Randomized Double Blind Clinical Study

Becky L. Rivoire¹, Nathan A. Groathouse¹, Stephen TerLouw¹, Kapil Dev Neupane², Chaman Ranjit², Bishwa Raj Sapkota², Saraswoti Khadge², Chatra B. Kunwar², Murdo Macdonald², Rachel Hawksworth², Min B. Thapa², Deanna A. Hagge², Melinda Tibbals³, Carol Smith³, Tina Dube³, Mark Wolff³, Eric Zhou⁴, Mamodikoe Makhene⁴, Robin Mason⁴, Christine Sizemore⁴, Patrick J. Brennan¹

¹Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, United States of America, ²Mycobacterial Research Laboratory, Anandaban Hospital, Kathmandu, Nepal, ³The EMMES Corporation, Rockville, Maryland, United States of America, ⁴Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, Maryland, United States of America

Abstract

Background: New tools are required for the diagnosis of pre-symptomatic leprosy towards further reduction of disease burden and its associated reactions. To address this need, two new skin test antigens were developed to assess safety and efficacy in human trials.

Methods: A Phase I safety trial was first conducted in a non-endemic region for leprosy (U.S.A.). Healthy non-exposed subjects (n = 10) received three titrated doses (2.5 µg, 1.0 µg and 0.1 µg) of MLSA-LAM (n = 5) or MLCwA (n = 5) and control antigens [Rees MLSA (1.0 µg) and saline]. A randomized double blind Phase II safety and efficacy trial followed in an endemic region for leprosy (Nepal), but involved only the 1.0 µg (high dose) and 0.1 µg (low dose) of each antigen; Tuberculin PPD served as a control antigen. This Phase II safety and efficacy trial consisted of three Stages: Stage A and B studies were an expansion of Phase I involving 10 and 90 subjects respectively, and Stage C was then conducted in two parts (high dose and low dose), each enrolling 80 participants: 20 borderline lepromatous/lepromatous (BL/LL) leprosy patients, 20 borderline tuberculoid/tuberculoid (BT/TT) leprosy patients, 20 household contacts of leprosy patients (HC), and 20 tuberculosis (TB) patients. The primary outcome measure for the skin test was delayed type hypersensitivity induration.

Findings: In the small Phase I safety trial, reactions were primarily against the 2.5 µg dose of both antigens and Rees control antigen, which were then excluded from subsequent studies. In the Phase II, Stage A/B ramped-up safety study, 26% of subjects (13 of 50) showed induration against the high dose of each antigen, and 4% (2 of 50) reacted to the low dose of MLSA-LAM. Phase II, Stage C safety and initial efficacy trial showed that both antigens at the low dose exhibited low sensitivity at 20% and 25% in BT/TT leprosy patients, but high specificity at 100% and 95% compared to TB patients. The high dose of both antigens showed lower specificity (70% and 60%) and sensitivity (10% and 15%). BL/LL leprosy patients were anergic to the leprosy antigens.

Interpretation: MLSA-LAM and MLCwA at both high (1.0 µg) and low (0.1 µg) doses were found to be safe for use in humans without known exposure to leprosy and in target populations. At a sensitivity rate of 20–25% these antigens are not suitable as a skin test for the detection of the early stages of leprosy infection; however, the degree of specificity is impressive given the presence of cross-reactive antigens in these complex native M. leprae preparations.

Trial Registration: ClinicalTrials.gov NCT01920750 (Phase I), NCT00128193 (Phase II)

Introduction

Despite the success of the widely applied multidrug therapy (MDT) in reducing the prevalence of leprosy, transmission continues with new case detection maintaining a steady rate in endemic regions of high burden areas, further emphasizing the importance of early detection [1]. A sensitive and specific test would facilitate early detection, allowing treatment prior to manifestation of physical disease, and reduced transmission, reactions, and patient disabilities. Such a test should be sensitive to the earliest immunological response to M. leprae, inexpensive for use in leprosy endemic regions, and simple to implement.
Intradermal skin testing through measurement of a delayed type hypersensitivity (DTH) reaction could meet the sensitivity attributes, and does so with Tuberculin DTH in the context of tuberculosis. [2,3] Earlier skin test antigens for leprosy (Lepromin A, Rees Antigen, and Convit’s antigen) [4,5] proved safe when used in humans. Lepromin A has been used for nearly 40 years [6,7] and provides a solid foundation of safety. In the present context, two new skin test antigens, Mycobacterium leprae soluble antigens (MLSA) devoid of glycolipids particularly lipoarabinomannan (LAM) called MLSA-LAM and MLCwA (M. leprae cell wall associated antigens), were generated, reflective of those of Convit and Rees in that they were derived from M. leprae grown in armadillos, but prepared under rigorous current good manufacturing practices (GMP) [8,9]. The primary goal of the application of these antigens in a clinical trial was to determine if the products were well tolerated in humans and if they exhibited diagnostic potential that would justify larger trials and eventual clinical implementation.

Methods

Ethics Statement

The Colorado State University (CSU) Institutional Review Board (IRB) for the protection of human subjects and the Nepal Health Research Council (NHRC) approved the protocols and informed consent forms, and certified that the studies were ethically cleared to proceed. All subjects provided written informed consent; no children were enrolled in the study. The Phase I safety non-endemic trial (registration number: NCT01920750) and Phase II safety and efficacy endemic trial (registration number: NCT00128193) were registered with ClinicalTrials.gov. The Phase I trial was not registered prior to implementation, because the trial was completed (February, 1999), before ClinicalTrials.gov registry was made available to the public (February, 2000). Retrospective registration of the Phase I trial was requested and obtained for publication by PLoS Tropical Diseases.

Intervention and Control Products

Test antigens were MLSA-LAM and MLCwA at 2.5 μg, 1.0 μg, and 0.1 μg/0.1 ml dose [10]. Control antigens were Rees MLSA [11], 20×1.0 ml vials at 1.0 μg dose received as a gift from Philip Draper and the late Joseph Colston (National Institute Medical Research, Mill Hill, UK) in Phase I; 0.9% sterile saline, approved for human use (Abbott Laboratories Inc., Abbott Park, IL) in Phase I and Phase II, Stage A; Tubersol Tuberculin PPD, 5 TU dose (Aventis Pasteur Inc., Swiftwater, PA) in Phase II Stage A and B and preliminary testing of Stage C-1a; and, Tuberculin PPD RT 23, 2 TU dose, solution for injection (Statens Serum Institute (SSI), Copenhagen, Denmark) in the remainder of Stage C-1 a/b. Strong reactions to the 5 TU dose of PPD prompted unblinding and SMC review for this one product. The outcome was a recommendation from the sponsor to use a lower dose for the remainder of Stage C-1 studies; this change was not expected to significantly impact the study results. The lower dose was not available from the same vendor; therefore, a new vendor was used.

Study Design

The Phase I clinical trial was conducted on MLSA-LAM and MLCwA in a non-endemic region for leprosy, while the Phase II clinical trial was conducted on both antigens in an endemic region for leprosy. The Phase II clinical trial included compulsory testing for safety and efficacy in healthy subjects without known exposure to leprosy and in target populations: borderline tuberculoid/tuberculoid (BT/TT) and borderline lepromatous/lepromatous (BL/LL) leprosy patients, household contacts of BL/LL leprosy patients (HC), and tuberculosis patients (TB).

Prior to initiation, the protocol was amended: 1) to allow testing in smaller group sizes (n = 20) to assure safety before ramping and to improve the likelihood of recruiting the requisite number of subjects; 2) to decrease the number of injections for subject comfort; and, 3) to add comparative in vitro assays to maximize the potential of this study (unpublished work). Stage C was divided into Stage C-1 for small scale studies and Stage C-2 for ramping to achieve statistical significance. Stage C-2 was not feasible, due to cessation of dedicated funding. Stage C-1 was divided into two parts, a and b, to test the high dose (1 μg) and low dose (0.1 μg) of each antigen. This protocol change enabled both the reduction of sample size and number of injections per subject, while remaining within the scope of the original protocol.

Participants in the Phase I safety trial (U.S.A.) were between the ages of 18 and 40 years, with a weight greater than 100 lbs (45 kg) for females and 140 lbs (64 kg) for males. In the Phase II trial, there were 68% male and 32% females enrolled in the study. The mean age of the subjects was 29 y, with a range of 18 to 60 y. Age did not vary significantly across study groups in Stages A, B, and C-1b, but there was a significant difference in age across study groups in Stage C-1a, p<0.05. Phase II participants had a weight greater than 30 kg for females and 38 kg for males.

The method for antigen administration and measuring induration was adapted from “Guidelines for Conducting Skin Test Surveys in High Prevalence Countries,” issued by the International Union against Tuberculosis and Lung Disease [12]. In the Phase I clinical trial, each participant received five 100 μl intradermal injections of titrated doses (2.5 μg, 1.0 μg, and 0.1 μg) of one of the two skin test antigens, one injection of 0.9% sodium chloride, and one injection of Rees MLSA control leprosy skin test antigen at a 1.0 μg dose, between both forearms. Participants in the Phase II, Stage A/B clinical trial, each received four injections of titrated doses (1.0 μg and 0.1 μg) of one of the two skin test antigens, one injection of 0.9% sterile saline (Stage A only), and one injection of Tuberculin PPD Tubersol 5 TU, between both forearms. Stage C-1a/b subjects received three injections of the high dose (1.0 μg) or low dose (0.1 μg) of each intervention and control antigen.

DTH responses were read at ~15 min, 48 h and 72 h post injection in the Phase I and Phase II, Stage A studies; prior to Stage B, the 48 h reading was dropped and a 7 day reading was added for convenience and safety. The 15 min observation was primarily a safety measure to gauge for immediate adverse events, such as anaphylaxis and a 30 min observation was added to the Stage C-1 studies to assure that subjects were not adversely affected from an added blood draw for in vitro testing (unpublished work). If a subject was observed to have an induration greater than...
Phase I Safety Trial - Non-Endemic U.S.A.

Phase I study commencement was December 1998 and study completion was February 1999. The total sample size of 10 subjects was divided between two antigen groups; 5 subjects received titrated doses of MLSA-LAM or MLCwA, plus control antigens. Healthy subjects without any known contact with tuberculosis or leprosy patients were recruited from the student body at CSU. All subjects were Tuberculin skin test negative when tested 3 weeks prior to study initiation. Subjects were assigned to either the MLSA-LAM or MLCwA antigen group based on a random sequence of integers. Study objectives were two-fold: to determine if MLSA-LAM and MLCwA were safe to use in humans as skin test antigens; and, to determine that the range of concentrations chosen for skin testing did not elicit a reactive response in a negative control group of human subjects from a region non-endemic for leprosy. The expected outcome for the Phase I clinical trial was that all three concentrations of the two leprosy skin test antigens, saline, and control Rees MLSA leprosy antigen would not evoke a skin test antigen response. Any untoward local reaction, such as severe erythema or necrosis, would result in those antigen doses being dropped from further testing.

Phase II Stage A/B Safety Trial - Leprosy Endemic Area in Nepal

The Phase II, Stage A study commenced in April 2002 and was completed in July 2002; Stage B study commenced in May 2003 and was completed in January 2004. The Phase II, Stage A and B clinical study was similar in design to the Phase I clinical trial, in that 100 subjects were divided between two groups; 50 subjects received titrated doses of MLSA-LAM and MLCwA, plus control antigens. Stage A was a preliminary safety screen with 10 subjects from a leprosy endemic region, whereas Stage B completed the safety trial with 90 subjects. Healthy subjects without any known contact with tuberculosis or leprosy patients were recruited from the Lalitpur Nursing Campus, Sanepa, Kathmandu and the Dhulikel Medical Institute, Dhulikel, Nepal, following delivery of a recruitment talk by a senior member of the research team from Anandaban Hospital, Kathmandu, Nepal, using the local Nepali language or English with immediate translation to Nepali.

To assess eligibility, volunteers were asked a series of health related questions, given a general physical exam and standard examination for signs of leprosy [16,17]. Females who were pregnant or lactating or individuals who were on corticosteroid or other immunosuppressive treatment, had cancer; diabetes, known hypersensitivities or allergies, expatriates other than those from India, had participated in an earlier Stage of this study, or were concurrently participating in another clinical trial were excluded from this study. Demographic information was collected, and BCG scar measured across the largest diameter (if present). Familial relationships were recorded for HC of leprosy patients only.

Phase II subjects were assigned an antigen and administration template based on a fixed block randomization sequence provided by the Data Coordinating Center (DCC; The EMMES Corporation, Rockville, MD). Antigens were concealed by antigen codes randomized for each antigen and antigen dose; both randomization schemes were sent to the clinical study principal investigator in the event that unblinding was necessary. Antigen codes were provided in separate envelopes, such that if only one antigen required unblinding, the others were not compromised.

The Phase II, Stage A and B clinical trials were performed by staff from Anandaban Hospital at the two sites. Study objectives were to evaluate the safety and to select a dose of MLSA-LAM and MLCwA causing minimal induration in healthy subjects without known exposure to clinical leprosy or tuberculosis that are living in a region endemic for leprosy. Subjects in the Phase II, Stages A and B clinical trials were expected to have a small (less than 10 mm) induration reaction to the leprosy skin test antigens and PPD, due to expected extensive cross-reactivity to M. tuberculosis, BCG vaccination, and/or environmental mycobacteria [18–20].

Phase II, Stage C Trial for Safety, Specificity, and Sensitivity - Leprosy Endemic Region

The Phase II, Stage C-1a study commenced in December 2006 and was completed in March 2008; Stage C-1b study lasted from May 2009 to September 2009. Two protocol amendments were filed, one in May 2007 to decrease the control antigen PPD dose; and, one in March 2009 to reduce the study size and to add comparative in vitro tests. The Phase II, Stage C-1a involved a high dose (1.0 μg) group (n = 80) and Stage C-1b a low dose (0.1 μg) group (n = 80). Each included 20 BT/TT leprosy patients, 20 BL/ LL leprosy patients, 20 HC of BL/LL leprosy patients, and 20 TB patients. Leprosy patients had one or more of the cardinal signs of leprosy including: hypopigmented or erythematous skin lesion(s) with loss of sensation; thickened peripheral nerves; or positive acid-fast bacilli (AFB) in slit skin smears or biopsy material [21]. Subjects with leprosy were either receiving or had completed standard MDT treatment for leprosy, no more than four years prior to study enrollment. Household contacts were determined to be healthy by history and physical examination and had resided in the same residence as the BL/LL leprosy index case for at least 6 months duration and within 6 months of this study. Tuberculosis patients had either at least two initial sputum smear examinations positive for AFB, or one sputum examination positive for AFB and radiographic abnormalities consistent with pulmonary tuberculosis, or one sputum specimen positive for AFB and culture positive for AFB. All patients had completed the intensive phase of chemotherapy for tuberculosis, but were still undergoing the continuation phase of therapy [22].

Leprosy patients and their household contacts were recruited at Anandaban Hospital, Kathmandu, and tuberculosis patients from...
the Tuberculosis Clinic of Patan Hospital, Kathmandu. Explanation of the study was guided by an appropriate flip chart and consent form translated into the native language, either Nepali or Hindi. In the case of illiterate subjects, information was read to them by a staff member. Randomization and blinding was the same as described for Phase II, Stage A/B.

Phase II, Stage C-1 studies were performed at the recruitment site by staff from Anandaban Hospital. A total of 10–12 ml of blood was collected from each participant prior to antigen administration for in-vivo laboratory testing involving quantitation of the release of IFNγ from lymphocytes after stimulation in whole blood and standard serology based on the phenolic glycolipid-I (PGL-I) antigen (unpublished work). Remaining subject samples were destroyed at the end of the study, per NHRC request.

The primary objective of the Phase II, Stage C-1 study was the assessment of safety in target populations: BT/TT and BL/LL leprosy patients, HC of BL/LL leprosy patients, and TB patients. The secondary objective was the assessment of efficacy of the two skin test antigens by comparing induration measurements following skin test administration. It was expected that BT/TT leprosy patients and some healthy contacts of leprosy patients would have large indurations at leprosy skin test sites due to 

M. leprae-specific T-cell anergy; and,

BL/LL leprosy patients would have negative indurations at all leprosy skin test sites due to 

M. leprae-derived antigen sites;

and, TB patients would react with an induration less than 10 mm at the leprosy antigen sites.

Statistical Analysis

For the Phase I clinical study, both antigens at each dose were not expected to elicit a DTH skin test response; therefore, a sample size of 10 subjects (5 per group) was expected to be satisfactory as a preliminary safety screen in a non-endemic region for leprosy. For the Phase II, Stage A clinical study, both antigens and antigen doses were expected to show minimal reactions, if any, and therefore a sample size of 10 subjects was expected to uncover any major safety concerns. For the Phase II, Stage B clinical study, the sample size was increased by 40 subjects for each antigen, to generate statistically significant data. Sample size consideration indicated that the study would be able to meet the primary statistical objectives should up to 10% of the subjects be lost to follow-up. The Phase II, Stage C-1a/b trial was designed to assess the safety and primary response measure of induration resulting from skin test antigen DTH responses in small numbers (n = 20) of participants within each of four different groups that theoretically may be at higher risk of serious adverse responses to novel antigens. The probability of observing one or more serious adverse events related to antigen administration was calculated. If the true serious adverse event rate is 10%, then there is an 85% chance of observing one or more serious adverse events in any one of the four groups with loss during follow-up of 10% of the subjects, or 88% if there is no loss during follow-up. Kruskal-Wallis tests were used to compare age by study group [23]. Efficacy analyses were performed using the receiver operating characteristic (ROC) curve [24]. GraphPad, Prism for Windows, version 6.0 (La Jolla, CA) was used for graphing and analyzing ROC curves.

Results

In the Phase I trial, eleven volunteers were recruited. Ten volunteers met the inclusion criteria and were enrolled in the study; one volunteer was unable to participate. One hundred and one volunteers were recruited for Stage A and B and one declined participation. The Phase II, Stage C-1a/b Trial CONSORT Flow Diagram is shown in Figure 1. Over two subsequent studies, one-hundred and sixty-one subjects (81 for Stage C-1a and 80 for Stage C-1b) were recruited; one HC in Stage C-1a declined participation and one BL/LL leprosy patient in Stage C-1b declined antigen administration.

Classification of leprosy patients in Stage C-1a were 20 of 20 (100%) BT subjects in the BT/TT group, and 12 of 20 (60%) BL and 8 of 20 (40%) LL subjects in the BL/LL group. Stage C-1b leprosy patients consisted of 17 of 20 (85%) BT and 3 of 20 (15%) TT subjects in the BT/TT group, and 14 of 20 (70%) BL and 6 of 20 (30%) LL in the BL/LL group. All but nine subjects were treated with multituberculosis MDT treatment, the others received paucibacillary MDT [25]. A total of 41 of 80 (51%) subjects between the two Stages had completed their treatment. None of the leprosy patients had a record of being skin tested with Lepromin A. History of type 1 leprosy reaction [26] in Stage C-1a was 6 of 20 (30%) for BT/TT and 5 of 20 (25%) for BL/LL subjects; and, Stage C-1b was 3 of 20 (15%) for BT/TT and 5 of 20 (25%) for BL/LL subjects. Erythema nodosum lepromatosum (ENL) reaction [27] history in Stage C-1a/b were recorded for 3 of 20 (15%) and 4 of 20 (20%) in BL/LL leprosy subjects.

Protocol Deviations

There were no protocol deviations that are believed to have affected product stability or resulted in adverse events. Deviations did not occur during the Phase I trial and Phase II, Stage A study. In the Phase II, Stages B and C-1 studies, the most frequent deviations were due to convenience of participant, and subject unable to comply.

Choice of Control Antigens

The Rees antigen (MLSA) served as the reference antigen for the small safety Phase I study conducted at CSU, but the NIH regulatory authority would not allow use in the safety and efficacy Phase II studies conducted in Nepal, because it was not commercially available or registered under a U.S.A. Investigational New Drug (IND) [28]. Lepromin A, prepared at the National Hansen’s Disease Program, Baton Rouge, LA, for WHO was no longer available and existing present day Lepromin A is prepared in India and Cuba, and not approved for U.S.A. studies. Tuberculin PPD, the skin test antigen for tuberculosis, was therefore used.

Dosages

The dose range of leprosy antigens (2.5 μg, 1.0 μg, and 0.1 μg) was chosen based on the Rees antigen dose of 1.0 μg [29], potency studies in sensitized guinea pigs [30], and antigen availability. The low dose (0.1 μg) was based on the lowest concentration of Rees antigen tested in the field [29,31], and this was the limit of detection for DTH responses in guinea pigs sensitized with 

M. leprae [10]. The standard Tuberculin test dose is equivalent to 5 TU of PPD-S, defined as the delayed skin test activation contained in a 0.1 μg/0.1 ml dose of PPD-S [32]. This dose is based on dry weight, whereas the leprosy dosage is based on measured protein content.

Safety

Safety was analyzed by reactogenicity and frequency, severity, and relationship of adverse events to the investigational product. Observations were tabulated by maximum number of events across all readings by antigen, except the 15 min reading post injection, which consisted of the raised bleb on the skin from
product administration. A reactogenic classification of a score of grade 3 or greater was recorded as an adverse event.

In the Phase I safety non-endemic study, of the ten participants tested with titrated doses of MLSA-LAM or MLCwA, only one subject elicited a DTH skin test response of induration against the 2.5 µg dose of MLCwA at 72 h. Induration measurements at 48 and 72 h were very similar and since the 48 h reading was dropped from the Phase II study, only the 72 h values are reported. Reactogenicity results indicated that the test antigens were well tolerated at all doses, but the 2.5 µg dose of both MLSA-LAM and MLCwA was responsible for 8 of 15 of erythema events and one of each induration or itching events noted. Although these were expected reactions for skin testing, they were not expected in healthy controls; therefore, as a precaution, the 2.5 µg dose was dropped from further testing. The final recommendations from the safety non-endemic study were to test the new leprosy skin test antigens in an endemic region for leprosy at 1.0 µg and 0.1 µg doses only.

In the Phase II safety trial in Nepal involving Stages A (10 subjects) and B (90 subjects) trial, individual subjects who were randomly assigned to a skin test antigen group, were reassigned a sequential number for reporting data (Table S1). Of participants tested in the Stage A study, only one subject in each group elicited a DTH skin test response of induration against the high (1.0 µg) dose of MLSA-LAM and MLCwA. Three subjects exhibited erythema against both antigens at the high dose, and one subject exhibited erythema against the low dose of MLCwA only. Itching was observed in two subjects with the high dose of each antigen (reactogenicity data on individual subjects is available from the lead authors).

Of the ninety participants tested in the Phase II, Stage B safety study, twelve subjects each elicited induration, and ten and eleven subjects showed erythema for the high dose of MLSA-LAM and MLCwA, respectively. Only one and two subjects showed erythema and induration at the low dose of both antigens, respectively. Itching was observed only in one subject at the high dose of MLCwA, and pain was observed in three or fewer subjects each at the high and low dose of MLSA-LAM and MLCwA.

Stage C-1a (high dose) and C-1b (low dose) 72 h induration measurements are provided as a supplement in Table S2, since this aspect of the study involved both safety and efficacy in the leprosy patients, contacts, and TB patients and most reactions consisted of mild to moderate induration and erythema, with only a few cases of mild pruritis and pain and one case of urticaria, infection, and blistering with MLSA-LAM at both the high and low dose. One case of bleeding at the site of injection was seen with MLSA-LAM at the low dose. The HC and TB groups had the highest number of reactions in the high dose study, whereas the
BT/TT and HC groups had more reactions in the low dose study. The BL/LL group had the lowest number of reactions across both the high and low dose of each leprosy antigens.

**Adverse events.** For the Phase II clinical trial, each adverse event (AE) was graded and coded by the MedDRA SOC [14]. Only one mild adverse event recorded as lymphangiitis was listed as possibly being related to one of the study products. The subject who experienced this AE was administered MLCoA and PPD. Five AEs, including two serious adverse events (SAEs), were deemed unrelated to the study antigens as determined by the Clinical Investigator and Medical Monitor. One mild AE described as a type I hypersensitivity reaction was observed in Stage C-1b in a BT/TT subject on day 12. The subject was given prednisolone, and the event was ongoing upon study termination. All other AEs were related to PPD reactions greater than 30 mm. Of the two SAEs, one subject, a 28 year old male with no past medical history, was hospitalized for appendicitis after the 28 day study period. This individual underwent an appendectomy on day 34 for appendicitis. The second SAE involved a death due to cerebral hemorrhage, possibly secondary to an A-V (arterio-venous) aneurysm. The subject was a 21 year old male with unknown personal or family medical history. The subject was on concomitant medications. The subject’s condition deteriorated and he died on day 25 of the study. Both the investigator and medical monitor assessed these events and deemed them unrelated to the study antigen.

**Efficacy**

**Baseline.** A baseline was derived for each antigen at each dose based on Phase II, Stage A/B data from healthy controls in an endemic region without known exposure to leprosy. Figure 2 shows the response to MLCoA high and low doses from the first five subjects in Stage A and the first 45 subjects in Stage B and MLSA-LAM high and low doses from the second five subjects from Stage A and the second 45 subjects from Stage B, each compared to PPD. Three individuals responded to one or the other leprosy skin test antigens only, and 14 responded to a leprosy antigen and PPD; whereas, 53 volunteers responded to PPD only.

**Relationship to BCG vaccination.** Since tuberculosis is prevalent in Nepal and many individuals were vaccinated with BCG, most subjects were expected to respond to PPD; hence, PPD testing was a measure of not only exposure to tuberculosis, but also BCG vaccination, and, to some extent, non-pathogenic environmental mycobacteria. In all stages of the Phase II trial, BCG vaccination scars were found in 163/260 (63%) subjects: 77/100 (77%) endemic controls (EC); 28/40 (70%) HC; 27/40 (68%) TB; and, 19/40 (48%) BL/LL. The mean size of vaccination scars were found in 163/260 (63%) subjects: 77/100 (77%) endemic controls (EC); 28/40 (70%) HC; 27/40 (68%) TB; and, 19/40 (48%) BL/LL. The mean size of 12/40 (30%) BT/TT; and, 19/40 (48%) BL/LL. The mean size of scars was 1.0–3. BCG vaccination history was compared to skin test responses. One BL/LL subject in the MLSA-LAM high dose group reacted with an induration of 20 mm. This subject was a 46 year old male with LL leprosy, who had been treated with MDT for a period of one month before enrolling in the high dose study. This participant was smear positive, had a bacterial index of 4.0, did not have a history of Type I or ENL reactions, had a single BCG scar, and, was using a topical steroid ointment for the treatment of mild eczema on two fingers. Comparison of mean induration measurements across all subjects showed a higher response in the BT/TT leprosy patients compared to HC with both antigens at the low dose. Antigens at the high dose showed a lower response in BT/TT leprosy patients compared to HC and TB patients. A significant increase in the number of responders and mean induration in TB patients and HC was seen with PPD, with fewer BL/LL leprosy patients responding overall.

**Antigen correlation.** With different responses being recognized between the two skin test antigens and dosages, results were compared by linear regression to look for correlations using the BT/TT group, albeit with fewer respondents. The highest correlation was found between the two leprosy antigens at the low dose with a covariance ($r^2$ value of 0.81, followed by the high dose with a covariance of 0.67. There was no correlation between MLSA-LAM high and low dose, or either antigen at either dose against PPD.

**Sensitivity and specificity.** Diagnostic statistics provide a measurable assessment of the leprosy skin test antigens [34]. Four statistics provide the foundation for assessing a diagnostic test: 1) sensitivity; 2) specificity; 3) positive predictive value; and, 4)
negative predictive value. Generally, a good diagnostic test is both sensitive and specific [35]. Sensitivity and specificity statistics have been calculated for the two new antigens and antigen doses compared to PPD in Table 3. Caution was taken when interpreting these values, because of the small sample sizes and limited BT/TT responders; PPV and NPV were not calculated due to limited positive responders. Results showed that MLSA-LAM and MLCwA at the low dose were highly specific (100% and 95%), but lacked sensitivity (20% and 25%). PPD as a diagnostic for tuberculosis was sensitive (90%), but not specific (41%).
Sensitivity of skin test antigens must be enhanced to develop a viable diagnostic test for leprosy. Preliminary results from *in-vitro* whole blood IFN-γ release assays (WB-IGRA) shown in Table 4, showed slightly improved sensitivity while retaining specificity at the high dose of each antigen; though full analysis of this data is not yet completed. A comprehensive comparison of the adaptive T-cell response against these two leprosy antigens by skin test and WB-IGRA, and serological response against PGL-I will be published soon.

**Discussion**

Study results were presented as trends, due to small scale sample sizes. Both antigens and antigen dosages are safe for use in BT/TT and BL/LL leprosy patients, HC of lepromatous leprosy patients, and TB patients. The diagnostic accuracy of both skin test antigens at the low dose (0.1 μg) was found to be inadequate in terms of sensitivity, but acceptable in terms of specificity. MLSA-LAM was shown to have slightly higher specificity than MLCwA at the low dose when comparing BT/TT leprosy patients against individuals infected with *M. tuberculosis*. At the high dose (1.0 μg), both antigens were limited in both sensitivity and specificity. Leprosy skin test antigens were found to be unresponsive in BL/LL leprosy patients confirming *M. leprae* specific anergy, yet capable of eliciting a response in some HC of BL/LL leprosy patients. A cut-off point for each antigen and antigen dose was calculated, but not with significance, due to limited positive responders in the BT/TT leprosy group.

Sensitivity and specificity were lacking with the Rees and Convit soluble antigens when tested in 2,602 Indian subjects [29]. A biomodal distribution of induration was seen with both antigens, but newly diagnosed leprosy patients, contacts, and non-contacts responded equally. In Northern Malawi, 15,630 subjects were tested with 5 batches of the Rees MLSA antigen prepared from two protocols [36]. With first and second generation antigens, a response from paucibacillary (similar to BT/TT) [37] leprosy patients was seen in 76% and 38% of the subjects, respectively; however, ECs responded in 42% and 32% of the subjects, resulting in a difference of 34% and 6% detection rates, respectively. These percentages represent responders over baseline and are close to the 10–20% detection rates seen with low dose MLSA-LAM and MLCwA antigens.

The low detection rate of known BT/TT leprosy patients with these antigens suggests that they are not suitable for detection of clinical leprosy. They do, however, elicit a response in 10–20% of HC, suggesting that they might be suitable for detection of pre-symptomatic leprosy [38]. The proportion of positive HC responding in these studies was consistent with documented risk of infection from a high bacillary index case at one in seven (14%) of 178 households studied [39]. Previous WB-IGRA studies with MLSA-LAM and MLCwA showed nearly identical results to these skin test studies, except that HC responded with a higher geometric mean than BT/TT leprosy patients; EC and TB patients did not respond [40]. These authors also found that recent exposure resulted in substantially stronger responses. Detection of BT/TT leprosy patients who were under treatment or completed treatment (51%) may have affected sensitivity results in these studies.

At the high dose compared to the low dose, both antigens elicited a response in a higher number of HC, TB, and EC subjects, but the number of BT/TT responders remained the same. These phenomena may be related to that observed when Leprosin A (Rees antigen) was shown to immunologically suppress the skin test response to PPD in both BT/TT and BL/LL leprosy.
Figure 3. Dot plot of induration measurements. Induration results are provided across five subject groups, including BL/LL leprosy patients ($n=19$ in low and $n=20$ in high dose group), BT/TT leprosy patients ($n=20$), HC ($n=20$), TB ($n=20$), and ECs ($n=50$). Low and high dose groups were combined to show PPD responses: BL/LL leprosy patients ($n=39$) and all other groups ($n=40$). Mean and standard deviation are shown. doi:10.1371/journal.pntd.0002811.g003
patients [41]. These data support the idea that there may be a difference in the antigenic profile that stimulates a response in pre-symptomatic, but not symptomatic leprosy.

The immunological environment of early leprosy is unknown; however, advances have been made in understanding the innate and adaptive immune mediated pathways that promote and control disease pathology [42,43]. In tuberculosis, the infection delays onset of adaptive immunity, which provides a window to establish a successful infection. Disease progression in tuberculosis, like leprosy, is then dependent on the immunological status of the host [44]. Striking similarities of the immunology and pathology between these two diseases suggest that TT leprosy could be a latent form of disease, under the control of the immune system, whereas LL leprosy is known to be the active form of disease with T-cell hyporesponsiveness [45]. Borderline forms are immunologically unstable and can downgrade depending on the immunological position of the host [33]. This continuum of immunological events probably occurs prior to and during manifestation of clinical symptoms, providing opportunities for an early clinical diagnostic tool.

Antigen specificity at the low dose was thought to be related to the removal of lipoglycans, including the immunosuppressive and cross-reactive LAM, lipomannan (LM), and phosphatidylinositol mannoside (PIM), and other lipids and lipoproteins [46–48]. Remaining proteins were numerous, but many shared sequence homology with *M. tuberculosis* [49]. Nonetheless, of the 100 EC tested, 77% had been vaccinated with BCG and 67% reacted with PPD, while only 2% reacted to the low dose leprosy antigens (2 with MLSA-LAM and 0 with MLCwA). This suggests that the leprosy antigens are detecting specific CMI responses resulting from an infection with *M. leprae*, implying that transmission has occurred in these few healthy subjects. Of the 20 TB subjects tested in the Phase II, Stage C-1b study, 95% (n = 19) reacted to PPD, but only 10% (n = 2) reacted to MLCwA and none reacted to MLSA-LAM. Another possibility is that the dose alone, or in combination with the removal of lipoglycans, resulted in high specificity. At the low dose, *M. leprae* specific proteins may be available for recognition, whereas at the high dose, those same proteins may be overpowered by ubiquitous mycobacterial proteins lending to cross-reactive responses with TB patients and EC exposed to environmental mycobacteria or vaccinated with BCG [20].

The strength of these studies was in the verification that new refined leprosy skin test antigens were immunologically active in
BT/TT leprosy patients, anergic in BL/LL leprosy patients, and highly specific in BT/TT leprosy patients. The skin test method was simple, easy for field use, and minimally invasive, potentially affording a feasible early diagnostic test tool. Limitations of these studies were difficulties in shipping materials through customs, lengthy document review and approvals, multiple stages in the Phase II protocol; prolonged duration to complete the study; political turmoil in the endemic country; intermittent communication services; and above all, unacceptably low sensitivity to warrant the larger scale trial originally planned.

Our findings do not support further work on the skin test method with MLSA-LAM and MLCwA. The future of diagnostic tests for pre-symptomatic leprosy needs to be specific, but foremost, must be sensitive to detect early infection with *M. leprae*.

### Table 2. Number of positive responders and mean induration compared to ECs.

| Antigen  | Dose | Group  | Number of Subjects | Mean Induration |
|---------|------|--------|--------------------|-----------------|
|         |      |        | No. Pos/Total (%)  | Ratio (Test/EC) |
|         |      |        | Mean (mm)          | Ratio (Test/EC) |
| MLSA-LAM | Low | EC     | 2/50 (4)           | na              |
|          |     | BT/TT  | 4/20 (20)          | 20/4 (5.0)      |
|          |     | BL/LL  | 0/19 (0)           | 0/4 (0.0)       |
|          |     | HC     | 2/20 (10)          | 10/4 (2.5)      |
|          |     | TB     | 0/20 (0)           | 0/4 (0.0)       |
| MLCwA    | Low | EC     | 0/50 (0)           | na              |
|          |     | BT/TT  | 5/20 (25)          | 25/1 (25.0)     |
|          |     | BL/LL  | 0/19 (0)           | 0/1 (0.0)       |
|          |     | HC     | 4/20 (20)          | 20/1 (20.0)     |
|          |     | TB     | 3/20 (15)          | 15/1 (15.0)     |
| MLSA-LAM | High| EC     | 10/50 (20)         | na              |
|          |     | BT/TT  | 2/20 (10)          | 10/20 (0.5)     |
|          |     | BL/LL  | 1/20 (5)           | 5/20 (0.3)      |
|          |     | HC     | 5/20 (25)          | 25/20 (1.3)     |
|          |     | TB     | 7/20 (35)          | 35/20 (1.8)     |
| MLCwA    | High| EC     | 8/50 (16)          | na              |
|          |     | BT/TT  | 3/20 (15)          | 15/16 (0.9)     |
|          |     | BL/LL  | 0/20 (0)           | 0/16 (0.0)      |
|          |     | HC     | 10/20 (50)         | 50/16 (3.1)     |
|          |     | TB     | 9/20 (45)          | 45/16 (2.8)     |
| PPD      | 5 TU| EC     | 67/100 (67)        | na              |
|          |     | BT/TT  | 25/40 (63)         | 63/67 (94)      |
|          |     | BL/LL  | 18/39 (46)         | 46/67 (69)      |
|          |     | HC     | 33/40 (83)         | 83/67 (124)     |
|          |     | TB     | 37/40 (93)         | 93/67 (139)     |

*aTo allow calculations, the EC percent positive has been changed to 1.0.*

doi:10.1371/journal.pntd.0002811.t002

### Table 3. Diagnostic test statistics – Skin test.

| Antigen  | Dose | Sensitivity | Specificity |
|---------|------|-------------|-------------|
|         |      | (BT/TT)     | (BL/LL)     | (EC) | (TB) |
| MLSA-LAM | Low | (4/20) 20%  | (0/19) 0%   | (50/50) 100% | (20/20) 100% |
| MLCwA    | Low | (5/20) 25%  | (0/19) 0%   | (50/50) 100% | (19/20) 95%  |
| MLSA-LAM | High | (2/20) 10%  | (1/20) 5%   | (43/50) 86%  | (14/20) 70%  |
| MLCwA    | High | (3/20) 15%  | (0/20) 0%   | (47/50) 94%  | (12/20) 60%  |

Diagnostic test statistics were calculated for each test method. Sensitivity (Se) is the likelihood to detect the presence of disease [(Total Positive (TP)/TP + False Negative (FN)]. Specificity (Sp) is the likelihood to detect absence of disease [(Total Negative (TN)/TN + False Positive (FP)]. PPD served as an antigen control. Statistics for detecting tuberculosis: Sensitivity is (36/40) 90%, specificity is (41/100) 41%.

doi:10.1371/journal.pntd.0002811.t003
Focus on the early T-cell response using multiple *M. leprae* specific antigens and immunological biomarkers may be required to enhance sensitivity. Promising proteins and peptides using cellular biomarkers to detect leprosy [38,50] and tuberculosis [51] have been recently reported. Comparable dose-dependent *in-vitro* studies with MLSA-LAM and MLCwA, as native antigens, would be expected to offer specificity and may improve sensitivity. Adding serology tests with specific antigens such as phenolic glycolipid-I (PGL-I) may increase early detection rates for BL/LL leprosy patients [52,53]. Despite the choice of test method, identification of the target population for pre-symptomatic leprosy, i.e. HC as identified in the COLEP study [54–56], will need to be determined. Testing in a large scale randomized study with follow-up will undoubtedly be required to reveal whether a future diagnostic test could tip the balance toward interrupting transmission.

### Supporting Information

#### Checklist S1 CONSORT checklist.

(DOC)

#### Checklist S2 STARD checklist.

(DOC)

#### Table S1 Phase II, Stage A/B - Induration measurements at 72 h. One hundred and one volunteers were recruited for Stage A and B, because one declined participation. A) In the Phase II, Stage A study, the 48 and 72 h induration measurements were very similar, and since the 48 hour response was dropped from Stage B, only the 72 hour values are provided for comparison. B) Phase II, Stage B study 72 h induration measurements. Response to skin test antigens: (*) a total of 30 individuals did not respond to either the intervention or to PPD, (**) a total of 5 individuals responded to one or the other antigens, but not PPD, (***) a total of 53 individuals responded to Tuberculin PPD only, and (****) a total of 14 individuals responded to both the intervention and PPD.

(DoC)

#### Table S2 Phase II, Stage C-1a/b (antigen high/low dose) induration at 72 h. Response patterns for individual subjects have been marked (*) no reaction to either intervention or PPD, (**) reaction to one or both interventions, but not to PPD, (***) reaction to PPD only, and (****) reaction to one or both intervention and PPD.

(DoC)

### Acknowledgments

We are grateful to study participants and team members for their contribution to these studies:

- Phase I Clinical Trial Team: Dr. Jane A. Higgins, Clinical Principal Investigator and Ms. Cheri L. Lazar, R.N., Skin Test Administrator, Hartshorn Health Center, CSU, Fort Collins, Colorado, U.S.A.
- Phase I SMC Members: Dr. Thomas Rea, Physician, University of Southern California, Los Angeles, California and Dr. Robert Gelber, Physician, University San Francisco California, San Francisco, California.
- Phase II, Stage A/B Clinical Staff: Dr. Ruth Butlin, Clinical Principal Investigator; Dr. Mark Macdonald, Clinical Principal Investigator (Phase II, Stage A); Dr. Rachel Hawkesworth, Clinical Principal Investigator (Phase II, Stage B); Dr. Murdo Macdonald, Study Coordinator (Phase II, Stage A/B); Dr. Jonathan Quinmpo, Regulatory Coordinator; Ishwor Raj Shrestha and the Mycobacterial Research Team, Niru Shrestha and the Nursing Department, Chaman Ranjit, Bishwa Sapkota, and Kapil Dev Neupane (Gold Standard Reader), Skin Test Administrators and Readers: Phase II, Stage A/B Clinical Trial, Anandaabnan Hospital, Kathmandu, Nepal.
- Phase II, Stage A/B Clinical Trial Location: Mrs. Rebecca Sinha, Campus Chief and Mrs. Radha Bangdil, Assistant, Lalitpur Nursing College, Sanepa, Kathmandu, Nepal; and, Dr. N. Sharma, Dhulikel Medical Institute, Dhulikel, Nepal.
- Phase II, Stage A/B SMC Members: Dr. Robert Gelber, UCSF (Chair); Dr. Thomas Rea, USC; Dr. Jane Higgins, CSU; and, Dr. Bharat Yadav (ISM), Patan Hospital, Kathmandu, Nepal.
- Phase II, Stage C Clinical Staff: Dr. Rachel Hawkesworth, Clinical Principal Investigator (Stage C-1a); Dr. Min Thapa, Clinical Principal Investigator (Stage C-1b); Dr. Murdo Macdonald, Study Coordinator (Stage C-1a); Dr. Deanna Haggie, Study Coordinator (Stage C-1b); Saraswoti Khadgi, Regulatory Coordinator; Ishwor Raj Shrestha and the Mycobacterial Research Team, Niru Shrestha and the Nursing Department, Chaman Ranjit, Bishwa Sapkota, and Kapil Dev Neupane (Gold Standard Reader), Skin Test Administrators and Readers, Anandaabnan Hospital, Kathmandu, Nepal.
- Phase II, Stage C Clinical Trial Location: Anandaabnan Hospital and the Tubercolosis Clinic of Patan Hospital, Kathmandu, Nepal.
- Phase II, Stage C SMC Members: Dr. Robert Gelber, (Chair) Physician, University San Francisco California, San Francisco, California, Dr. Thomas Rea, Physician, University of Southern California, Los Angeles, California, Dr. David Scollard, National Hansen’s Disease Program, Baton Rouge, LA, and, Dr. Bharat Yadav (ISM), Patan Hospital, Kathmandu, Nepal.
- Data Coordinating Center: Ms. Melinda Tibbals and Ms. Carol Smith, Coordinators; Drs. Tina Dubu, Dewei She and Mark Wolfle, Biostatisticians, The EMNES Corporation, Rockville, MD.
- Additional Support: Dr. Joseph LeMaster, Phase II Protocol Statistics.
- Product Development: Dr’s. Becky Rivoire and Stephen TerLouw, Manufacturer and Study Coordinator; Mr. Nathan Groathouse, Quality; and, Dr. Patrick Brennan, Principal Investigator, Fort Collins, CO.
- Study Sponsor: Linda Rosendorf, IND Coordinator; Elizabeth Horigan and Eric Zhou, Regulatory Affairs Specialists; Dr. Mamodikoe Mekhene, Medical Monitor; Robin Mason, Protocol Champion; Dr.’s Ann Ginsberg and Christine Szimore, Program Officers.

### Author Contributions

Conceived and designed the experiments: BLR ST KDN MMac RH MT CSM MW MMak RM CSi PJB. Performed the experiments: BLR NAG ST KDN CR BRS SK CBK MMac RH MBT DAH MT CSM TD DS MW EZ. Analyzed the data: BLR ST DAH MT CSM TD DS.

Conceived or contributed analysis tools: BLR RH MW EZ RM CSi PJB. Wrote the paper: BLR PJBJ. Regulatory control: EZ RM.

---

Table 4. Diagnostic test statistics – WB-IGRAa.

| Antigen  | Dose | Cut-off (IU/ml) | Sensitivity (BT/TT) | Specificity (TB) | P value |
|----------|------|----------------|---------------------|-----------------|---------|
| MLSA-LAM | Low  | 1.30           | 83%                 | 53%             | 0.150   |
| MLCwA    | Low  | 1.20           | 72%                 | 53%             | 0.500   |
| MLSA-LAM | High | 0.14           | 47%                 | 95%             | 0.001   |
| MLCwA    | High | 0.22           | 32%                 | 95%             | 0.030   |

aPreliminary unpublished results.

doi:10.1371/journal.pntd.0002811.t004
References

1. (2012) WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser: 1–61, 61 p following 61.
2. Snider DE, Jr. (1982) The tuberculin skin test. Am Rev Respir Dis 125: 108–116.
3. Huebner RE, Schein MF, BasB, Jr. (1993) The tuberculin skin test. Clin Infect Dis 17: 968–975.
4. Corvitt J, Sampson G, Zaniga M, Smith PG, Prata J, et al. (1992) Immunophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet 339: 446–450.
5. WHO IMMLEP (1982) Vaccination trials against leprosy: a meeting of the epidemiology subgroup of Scientific Working Group on the Immunology of Leprosy, Geneva, 11–13 February, 1982. WHO Document TDR/IMMLEP/ EDP 85: 7–8.
6. Meyers WM, Kvernes S, Binford CH (1975) Comparison of reactions to human and armadillo lepromins in leprosy. Int J Lepr Other Mycobact Dis 43: 218–225.
7. Millar JW, Gannon C, Chan CS (1975) Comparison in leprosy patients of Fernandez and Mitsuda reactions using human and armadillo antigens. A double-blind study. Int J Lepr Other Mycobact Dis 43: 226–233.
8. FDA (2011) Current Good Manufacturing Practice for Finished Pharmaceuticals. Points to Consider 4.3.
9. FDA (2011) Investigational New Drug Application; Responsibilities of Sponsors and Investigators. 21 CFR 312 Subpart D.
10. Holland SM (2001) Nontuberculous mycobacteria. Am J Med Sci 321: 49–55.
11. Parrajar D, Das R, Chauhan DS, Sharma VD, Lavania M, et al. (2009) Identification of environmental mycobacteria isolated from Agra, north India by EDP 85: 7–8.
12. Arnadottir T, Rieder HL, Trebucq A, Waaler HT (1996) Guidelines for conducting tuberculin skin test surveys in high prevalence countries. Tuberc Lung Dis 77 Suppl 1: 1–19.
13. Sanodi Pasteur Limited Toronto Ontario Canada (2009) Tuberculin, Tuberculin Purified Protein Derivative (Mantoux). Package Insert R19-0905 Canada.
14. ICH (2012) MDDA Term Selection. Technical Requirements for Registration of Pharmaceuticals for Human Use. Points to Consider 4.3.
15. FDA (2011) Investigational New Drug Application; Responsibilities of Sponsors and Investigators. 21 CFR 312 Subpart D.
16. Britton WJ, Lockwood DN (2004) Leprosy. Lancet 363: 1209–1219.
17. Fine PE, Floyd S, Stanford JL, Nkhosa P, Kasunga A, et al. (2001) Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy. An Bras Dermatol 86: 787–792.
18. Lecliang MM, Devic JJ, Gatosson C, Boumont PM (2000) Systematic reviews of diagnostic test accuracy. Ann Intern Med 149: 889–897.
19. Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39: 561–577.
20. Natarajan PS, Ponnushan GM, Rees RJ, Chavulla D (1998) Delayed-type hypersensitivity to Mycobacterium leprae soluble antigen as a test for infection with the leprosy bacillus. Int J Epidemiol 27: 713–721.
21. Organization. WH (1982) Report of the Eleventh and Twelfth Meetings of the Steering Committee of the Scientific Working Group on the Chemotherapy of Leprosy. Geneva, March 30–31 and Oct 10. TDR/THELEP-SC (11–12) 86: 1–6.
22. Geluk A (2013) Challenges in immunodiagnostic tests for leprosy. Expert Opin Med Diagn 7: 263–274.
23. Douglas JT, Cellona RV, Fajardo TT, Jr., Abalos RM, Balagon MV, et al. (2004) Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. Clin Diagn Lab Immunol 11: 58–64.
24. Manandhar R, LeMaster JW, Butlin CR, Brennan PJ, Roche PW (2000) Interferon-gamma responses to candidate leprosy skin-test reagents detect exposure to leprosy in an endemic population. Int J Lepr Other Mycobact Dis 68: 40–48.
25. Sengupta U, Sinha S, Ramu G, Lamb J, Jauny, J (1987) Suppression of delayed-type hypersensitivity skin reactions to tuberculin by M. leprae antigens in patients with lepromatous and tuberculoid leprosy. Clin Exp Immunol 68: 1–5.
26. Ottenhoff TH (2012) New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol 20: 419–428.
27. Morfin RL (2010) The innate immune response in leprosy. Curr Opin Immunol 22: 48–54.
28. Bhat RM, Prakash C. (2012) Leprosy: an overview of pathophysiology. Interdiscip Perspect Infect Dis 2012: 181089.
29. Kumar S, Naqvi RA, Khanna N, Rao DN (2011) Distinction of HLA-DR, rapid, deregulations of Lck-ZAP-70-Chk-b cross-talk and mI181a towards T cell hyporesponsiveness in leprosy. Med Immunol 48: 1178–1180.
30. Chatterjee D, Khoo KH (1998) Mycobacterial lipoarabinomannan: an extraordinary lipoheteroglycan with profound physiological effects. Glycolobiol 8: 113–120.
31. Torvelles JB, Seling PA, Zhang N, Koen MA, McNeil MR, et al. (2012) Isolation of a distinct Mycobacterium tuberculosis mannos-capped liposarabi- nomannan isoform responsible for recognition by CD1b-restricted T cells. Glycoconjugate J 22: 1118–1127.
32. Barnes PF, Chatterjee D, Abrams JS, Lu S, Wang E, et al. (1992) Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure. J Immunol 149: 341–347.
33. Marques MA, Neves-Ferreira AG, da Silveira EK, Valente RH, Chapeaurouge A, et al. (2008) Deciphering the proteomic profile of Mycobacterium leprae cell envelope. Proteomics 8: 2477–2491.
34. Zhou, Obschowskii, McClish (2002) Statistical Methods in Diagnostic Medicine. Wiley.
35. Organization WH (2012) Expert Committee on Leprosy, 8th Report. N.ervonomy, World Health Organization, United Nations, New York.
36. Nery JA, Bernardes Filho F, Quintanilha J, Machado AM, Oliveira Sde S, et al. (2013) Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy. An Bras Dermatol 88: 787–792.
37. Voorcen CG, Post EB (2013) A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction. PLoS Negl Trop Dis 7: e2240.
38. Tremolada I, Milani D, Buscaglia A, et al. (2012) The role of Mycobacterium leprae phenolic glycolipid I (PGL-I) in serodiagnosis and in the pathogenesis of leprosy. Lepr Rev 82: 344–357.
39. Samrajiy LH, Stefani MM, Oliveira RM, Sousa AL, Iveton GC, et al. (2013) Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect Dis 11: 26.
40. Moet FJ, Osamk I, Faber R, Pahan D, Richardson JH (2004) A study on transmission and a trial of chemoprophylaxis in contacts of leprosy patients: design, methodology and recruitment findings of COLEP. Lepr Rev 75: 376–381.
41. Moet FJ, Pahan D, Osamk I, Richardson JH (2000) Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ 336: 761–764.
42. Fernsra SG, Pahan D, Moet FJ, Osamk I, Richardson JH (2012) Patient-related factors predicting the effectiveness of rifampicin chemoprophylaxis in contacts: 6 year follow up of the COLEP cohort in Bangladesh. Lepr Rev 83: 292–304.